The UAE will be the first country in the world after the US Food and Drug Administration (FDA) to introduce a device to treat diabetes type II.
Dr Amin Hussein Al Amiri, Assistant Undersecretary for Public Policy and Licensing of the Ministry of Health and Prevention (MOHAP), said that it is part of the UAE’s plan to combat the risks associated with diabetes and provide the patients with latest global treatment systems.
He said the UAE has developed innovative drugs to fight cancer, viral hepatitis, rheumatism, heart disease, diabetes, high blood pressure and other diseases.
MOHAP said it has been coordinating with a French company for the treatment of type II diabetes, which is expected to be available in January, once approved by the FDA.
The new treatment is a small device made of titanium which is the size of matchmaker and is placed under the skin and under the chest for both men and women.
It contains a micro pump that injects the daily dose necessary for the patient with type II diabetes regularly and lasts up to six months, which is expected to reach up to a period of 12 months in mid-2018.
Earlier this year, a report claimed the per capita cost of treating diabetes in Saudi Arabia, the UAE and Qatar are among the highest in the Middle East and North Africa (MENA) region.
The International Diabetes Federation (IDF) estimates on average 13.6 percent of the adult population between 20 and 79 years in the region have been diagnosed with diabetes, which is higher than the global average of 8.5 percent.
BMI Research said Saudi Arabia, the UAE and Qatar have one of the highest diabetes-related expenditure on a per capita basis, reported at $1,145, $2,156 and $2,868 respectively.